NCT02555189 2026-04-22
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Thomas Jefferson University
Phase 1/2 Terminated
Clinical Trials
34 trialsNCT03395197 2026-04-22
TALAPRO-2
Pfizer
Phase 3 Active not recruiting
NCT05457257 2026-04-21
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
Phase 4 Active not recruiting
NCT06136650 2026-04-21
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05997615 2026-04-20
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT06551324 2026-04-20
MEVPRO-1
Pfizer
Phase 3 Recruiting
NCT06863272 2026-04-20
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04076059 2026-04-17
China ARCHES
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03460977 2026-04-16
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
NCT06576037 2026-04-16
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06629779 2026-04-16
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Pfizer
Phase 3 Recruiting
NCT06991556 2026-04-16
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis
Phase 2 Recruiting
NCT07226986 2026-04-16
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis
Phase 1/2 Recruiting
NCT06592924 2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT02225704 2026-04-13
Radium-223 in Combination With Enzalutamide
Cancer Trials Ireland
Phase 2 Completed
NCT02960022 2026-04-13
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Phase 2 Recruiting
NCT03869762 2026-04-13
DICE
Cancer Trials Ireland
Phase 2 Terminated
NCT05818683 2026-04-13
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06616155 2026-04-13
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Recruiting
NCT04787744 2026-04-08
VA STARPORT
VA Office of Research and Development
Phase 2/3 Recruiting
NCT06136624 2026-04-08
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07287150 2026-04-08
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT04821622 2026-04-07
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Pfizer
Phase 3 Active not recruiting
NCT06632977 2026-04-07
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT04363164 2026-04-06
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05112965 2026-04-06
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06120491 2026-04-03
EvoPAR-PR01
AstraZeneca
Phase 3 Recruiting
NCT03899155 2026-04-01
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT06734130 2026-04-01
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03674814 2026-03-31
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
University of Chicago
Phase 1 Completed
NCT04221542 2026-03-30
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
Phase 1 Recruiting
NCT07028853 2026-03-30
MEVPRO-3
Pfizer
Phase 3 Recruiting
NCT06096870 2026-03-25
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting